PDUFA IV: You Can't Always Get What You Want
This article was originally published in RPM Report
Executive Summary
Former Senate HELP Committee FDA counsel Steven Irizarry looks ahead at the reauthorization of PDUFA and what drug companies should expect in the latest round of negotiations.
You may also be interested in...
FDA in a Shutdown: The Plan Still Matters
A government shutdown was averted but not until federal agency’s were forced to communicate their shutdown plans to employees and the public. Those plans may have a lingering impact—and not just because the threat of a shutdown is sure to arise again.
Omnitrope Clears FDA: Is the Next Hurdle Congress?
The debate over an abbreviated biologics pathway took a big step forward with the Food & Drug Administration's approval of Sandoz' recombinant human growth hormone Omnitrope. The approval itself is precedent setting, but the bigger ramifications are political: the action steps up the pressure on Congress to address the issue head-on.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.